# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹27,150 Cr** FY26 (+17%) · **₹7,590 Cr** Q4 (+16% YoY / +11% QoQ) * **EBITDA:** **₹8,480 Cr** FY26 (+20%) · **₹2,560 Cr** Q4 (+20% YoY / +41% QoQ) * **EBITDA Margin:** **31.2%** FY26 · **33.7%** Q4 * **Adjusted Net Profit:** **₹5,460 Cr** FY26 (+15%) · **₹1,590 Cr** Q4 (+15% YoY / +43% QoQ) * **Leverage:** **0.5x** Net Debt/EBITDA (as of Mar-26) ## B. Revenue & Profitability * **Record Performance:** Fiscal 2026 marked a milestone year with robust double-digit growth and record operating profitability, exceeding initial expectations even after adjusting for inorganic contributions. * **Depreciation & Amortization Dynamics:** Quarterly depreciation includes capitalized licensing fees from the Mirabegron settlement; these specific charges, alongside a **$75 million** amortization and ongoing royalties, will persist until **September 2027**. * **Incremental Revenue Streams:** Supply to Agenus via BOT-BAL is currently contributing a modest **₹10 to ₹15 crore**, representing incremental rather than core volume. ## C. Margin Profile * **Profitability Drivers:** Achieved peak operating margins through a combination of favorable product mix, operating leverage, and forex tailwinds. * **Amplitude Business Strength:** The Amplitude segment is currently profitable with margins **exceeding 20%**, with management targeting further scaling and margin expansion in the medium term. ## D. Cash Flow & Capital Allocation * **Cash Flow Compression:** Despite record EBITDA, FY26 operating cash flow declined to **₹2,000 crore** due to Mirabegron settlement payments, higher capex, and working capital needs from recent acquisitions. * **Strategic Reinvestment:** Capital allocation is prioritized toward 505(B)(2) specialty products, new platform capabilities, and disciplined bolt-on acquisitions. * **Leverage Outlook:** Following the Assertio acquisition and buyback, net debt is projected to rise to **₹7,000 crore**, bringing leverage to just under **1.0x** Net Debt/EBITDA—a level management views as comfortable. * **Operational Efficiency:** Management maintains a "best-in-class" view of its working capital, citing healthy inventory and receivable levels despite the complexity of integrating new assets. --- # 2. India & Consumer Business ## A. Key Figures * **Branded Formulations (India) Growth:** **15%** YoY (Outperforming IPM) * **Chronic Segment Mix:** **46.3%** of portfolio (+620 bps over 3 years) * **Consumer Segment Growth by Category:** **39.7%** Skin & Haircare · **9.4%** Food & Nutrition * **Oncology Revenue:** **>₹800 Cr** ## B. Branded Formulations * **Market Outperformance:** Sustained double-digit momentum driven by a strategic shift toward chronic therapies and product differentiation. * **Growth Guidance:** Management expects to outpace the Indian Pharmaceutical Market (IPM) by **200-400 basis points**, fueled by biosimilar monetization and innovation. * **Operational Efficiency:** No immediate requirement for additional medical representative (MR) headcount; growth is currently powered by "booster brands" and core therapy building. * **First-to-Market Advantage:** Secured **#2 market rank** in the Semaglutide space via a reliable supply chain and a proprietary reusable pen device. * **Oncology Leadership:** Now the largest domestic player in Oncology, leveraging first-to-market launches of **Pertuzumab** and **Nivolumab**. ## C. Consumer Wellness * **Strategic Pivot:** Business focus is shifting toward **premiumization** and expansion into the Nutrition and VMS (Vitamins, Minerals, and Supplements) categories. * **Digital Scaling:** Accelerating e-commerce and digital presence through the **Comfort Click acquisition**. * **Forward Momentum:** Segment projected to maintain healthy double-digit growth following strong initial acceptance of new product launches. ## D. Therapy Mix & Trade Generics * **Diversification Strategy:** Broad-based outperformance across Cardiology, Respiratory, and Dermatology, with a new strategic entry into **Nephrology**. * **Oncology Tailwinds:** Growth supported by increased government scheme penetration and robust patient support programs. * **Trade Generics Positioning:** Segment remains a non-core "cash cow" component of the business, with management prioritizing branded innovation over generic volume. --- # 3. US & International Markets ## A. Key Figures * **North America Revenue:** **₹2,950 Cr** Quarterly (+5% QoQ) * **International Formulations Revenue:** **₹800 Cr** Quarterly (+45% YoY) * **International Growth Rate:** **>40%** Full Year * **US Regulatory Activity:** **3** ANDA Filings · **9** Approvals · **6** New Launches * **Specialty Market Share (Rolvedon):** **~4%** Volume Share ## B. North America Performance * **Resilient US Growth:** Robust quarterly performance driven by volume expansion and specialty traction, successfully offsetting increased competition and minimal contributions from **Revlimid**. * **Market Leadership:** Currently ranked as a **top 3 player** in the U.S. generic space, underpinned by a differentiated R&D pipeline and strategic partnerships. * **Short-term Outlook:** Management anticipates steady performance over the next two quarters, with significant product-specific traction expected in the **latter half of the year**. ## C. Specialty & Rare Disease * **Portfolio Scaling:** The specialty segment is transitioning toward profitability; the **Sentynl** business has reached break-even with **3** rare disease products now marketed. * **Strategic Pipeline:** Growth is anchored by the **505(b)(2)** pipeline and the in-licensing of **two large biosimilars**, with a significant scale-up projected to materialize by **FY28**. * **Clinical Differentiation:** **Rolvedon** is positioned as a novel long-acting GCSF (not a biosimilar), offering a competitive advantage through **same-day administration**. * **Go-to-Market Strategy:** Zydus will pursue a self-directed US launch for **Saroglitazar (PBC)**, while reserving international co-partnering opportunities for post-US approval. ## D. Emerging Markets & Europe * **High-Velocity Expansion:** Exceptional double-digit momentum sustained by a therapy-led approach and rapid scaling in newly entered geographies. * **Global Registration Strategy:** Implementing a registration plan for a new differentiated formulation across **20+ markets** to capture government cost-benefit demand. * **Future Catalysts:** The biologics segment is slated for significant EM expansion over the next **3 years**, with the **China** launch of **Desidustat** targeted for **Q2 FY27**. --- # 4. R&D & Innovation Pipeline ## A. Key Figures * **R&D Allocation:** **~50%** Generics/Value-added · **>40%** NCEs, Biologics, and Vaccines * **Product Pricing:** **25%** of reference drug cost (Tishtha™) ## B. Biosimilar Progress * **First-to-Market Launches:** Achieved global and domestic milestones with the world’s first Nivolumab biosimilar and India’s first indigenous Aflibercept, significantly expanding patient access. * **US Market Entry:** Strategically timing US biologics entry to leverage regulatory shifts; Pembrolizumab biosimilar (FYB206) has completed clinical development ahead of a planned **USFDA filing**. * **Long-term Scaling:** Management projects a major scaling milestone for the global biosimilars business within **three years**, with full-scale financial impact anticipated by **FY29–FY30**. * **Near-term Pipeline:** Ranibizumab launch expected by year-end, providing immediate momentum for the projected growth in **FY27 and FY28**. ## C. NCE & Clinical Trial Updates * **Investment Pivot:** Future R&D spending is shifting toward an increased weighting for NCEs and biologics while maintaining absolute spend levels for generics. * **Advanced Clinical Pipeline:** Initiated Phase-III trials for a second biosimilar ADC and two trials for the novel anti-malarial **Zintrodiazine**; Phase-I initiated for a new novel biologic. * **Metabolic Franchise:** Recruitment for a large Phase 4 MASH trial in India is expected to close within **two quarters**, while PBC data for Saroglitazar is slated for presentation at **EASL 2026**. ## D. 505(b)(2) & Specialty Strategy * **Portfolio Acceleration:** The specialty pipeline, including the Sitagliptin and LiqMeds portfolios, is positioned for high-margin scaling following the filing of **2 new product dossiers** in April 2026. * **Oncology Launch Timeline:** A partnered 505(b)(2) supportive oncology product is already filed, with approval and commercialization expected within **9 to 12 months**. * **Revenue Contribution:** Initial scaling of the specialty business is anticipated within the current fiscal year, building upon the established revenue base. --- # 5. M&A & Strategic Partnerships ## A. Key Figures * **Medical Devices Revenue:** **₹330 Cr** * Saro Commercialization Investment: **70 million** current year allocation ## B. Assertio & Oncology Strategy * **Strategic Oncology Pivot:** The Assertio Holdings acquisition provides an immediate high-scale US commercial platform for oncology supportive care, anchored by the FDA-approved biologic **Rolvedon**. * **Market Positioning:** Management intends to leverage deep Medicare Part B relationships and the existing **Beizray** platform to scale a highly differentiated, high-margin specialty business. * **Financial Accretion:** The Assertio transaction is expected to be accretive upon closure, generating synergies rather than incremental costs. * **Specialty Pipeline:** While no progress was reported on a specialty acquisition for the Saroglitazar launch, the company is actively seeking **bolt-on 505(B)(2) opportunities** in orphan and rare diseases. ## C. Licensing & Consumer Wellness * **Semaglutide Market Capture:** To maximize "share of voice" in the competitive India diabetes market, Zydus out-licensed its semaglutide brands to **Lupin and Torrent Pharma** for co-marketing. * **VMS Expansion:** The integration of UK-based **Comfort Click** has established a high-growth Vitamin, Mineral, and Supplement (VMS) presence across the UK, EU, and US. * **Wellness Profitability:** The Comfort Click business met performance targets post-acquisition and achieved **EPS accretion** in the fourth quarter. * **Rare Disease Licensing:** Secured a licensing agreement with **PRG S&T** for Progerinin, a potential second therapy for Hutchinson-Gilford Progeria Syndrome. ## D. Medical Device Platform * **Core Vertical Establishment:** Following the acquisition of **Amplitude Surgical**, medical devices have been formalized as one of the company's three core business pillars. * **Growth Horizon:** Currently in a "platform-building" phase, management expects strong momentum in **3 to 4 years** driven by geographic expansion and cost synergies. * **Sector Focus:** Targeting high-end MedTech segments including cardiology, nephrology, and orthopedics, supported by a new **dialyzer membrane facility**. * **Distribution Optimization:** Recently acquired **FBC Medical** to consolidate sales and distribution for the Amplitude business. --- # 6. Manufacturing & Operations ## A. Facility Compliance & Capacity * **Regulatory Milestone:** The Ahmedabad SEZ oncology injectable plant successfully received an **Establishment Inspection Report (EIR)** following a November 2025 pre-approval inspection. * **Strategic Asset Integration:** Newly acquired facilities are being leveraged to strengthen U.S. manufacturing, specifically for **BOT-BAL supply** and onboarding new specialty business partners. * **Utilization Timeline:** The Zylidac facility (ex-Agenus) is projected to require **2 years** for capability building and approximately **3 years** to reach peak utilization as the product pipeline scales. ## B. Operational Efficiency & Supply Chain * **Digital Acceleration:** Management is embedding **AI, advanced analytics, and automation** across the value chain to drive operational efficiency and enhance stakeholder service levels. * **Margin Protection Strategy:** In response to geopolitical volatility and rising logistics costs, the company is implementing **aggressive cost optimization** and sourcing rationalization. --- # 7. Risks & Regulatory Factors ## A. Key Figures * **Revenue Base:** **$300M–$310M** Current quarterly run-rate * **Launch Timeline:** **Late 2024 / Early 2025** Expected window for new formulations ## B. Pricing & Competition * **Volume-Led Growth Strategy:** Management clarified that domestic formulation expansion is driven by volume gains rather than pricing, as the portfolio faces natural price deflation over time. * **Market Share Defense:** To counter the government-led shift toward trade generics, the company is pivoting toward product differentiation and an innovation-heavy pipeline to protect core brand equity. * **Portfolio Erosion:** Anticipated competitive entry for **Mira** is expected to pressure the current revenue base in upcoming periods. ## C. Regulatory Approvals * **Desidustat Global Milestones:** Secured regulatory approval in China for renal anemia (world’s second-largest market) and received **US FDA Orphan Drug Designation** for sickle cell disease. * **Saroglitazar Pipeline:** A New Drug Application (NDA) has been submitted to the FDA for Primary Biliary Cholangitis (PBC); awaiting formal acceptance to establish a PDUFA goal date. ## D. Geopolitical & Supply Chain Risks * **Macro Volatility:** Management cited limited visibility into supply chain impacts over the next **three to six months** due to the volatile global environment, adopting a reactive posture to emerging disruptions. --- # 8. Guidance & Outlook ## A. Key Figures * **Revenue Growth (FY27):** **High teens** consolidated · **Single-digit** North America [8, 16] ## B. Revenue Targets * **Sustained Momentum:** Consolidated top-line is projected to maintain a strong double-digit trajectory in FY27 despite a high base in the previous year. * **Regional Performance:** North American operations are expected to grow modestly on a sustainable quarterly base, while SEMA forecasts have been revised upward following robust Indian market demand. [14, 16] ## C. Margin & Profitability Guidance * **Profitability Resilience:** Management expects to maintain robust margins exceeding 24%, factoring in competitive pressures on key products like **Revlimid and Mirabegron**. * **Investment Absorption:** Guidance accounts for incremental commercialization costs for new assets and the **Assertio** acquisition while maintaining a disciplined R&D allocation. [9, 10] ## D. Capex & Long-term Scaling * **Expansionary Capex:** Significant capital outlay planned for FY27 to support multiple ongoing growth initiatives and infrastructure scaling. * **R&D Commitment:** Long-term innovation spend is expected to stabilize as a percentage of revenue, reflecting a balanced approach to future growth and quarterly profitability.